Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC filing details

Document Details

Form
4
Filing Date
Oct 9, 2020
Document Date
Oct 7, 2020
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp
Filer
Goldberg Mark Alan